NCT05698303 2023-01-26A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple MyelomaNanjing IASO Biotechnology Co., Ltd.Phase 1 Unknown12 enrolled